Financial Performance - Total revenue for 2025 reached RMB 137,880.84 million, a year-on-year increase of 40.63%[2] - Net profit attributable to shareholders of the parent company was RMB 17,319.98 million, reflecting a 416.37% increase compared to the previous year[2] - Basic earnings per share rose to RMB 0.43, representing a 437.50% increase compared to the previous year[2] - The weighted average return on equity increased to 16.85%, up 12.71 percentage points from the previous year[2] Assets and Equity - Total assets at the end of the reporting period were RMB 372,436.22 million, a 54.20% increase from the beginning of the period[3] - Shareholders' equity attributable to the parent company increased by 160.76% to RMB 217,491.14 million[3] Research and Development - R&D expenses amounted to RMB 43,805.44 million, up 35.23% year-on-year, indicating a strong commitment to innovation[2] - The company maintains a high gross margin through continuous R&D investment and lean management practices[4] Market Expansion - The growth in operating performance was driven by the expansion into overseas markets and the recovery of the domestic biopharmaceutical industry[4] Capital Structure - The company raised net funds of RMB 114,405.93 million through its A-share listing, significantly improving its capital structure[5]
百奥赛图(688796) - 2025 Q4 - 年度业绩